BlackRock Advisors LLC acquired a new stake in Audentes Therapeutics, Inc. (NASDAQ:BOLD) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 200,072 shares of the company’s stock, valued at approximately $3,564,000.

Other institutional investors have also recently made changes to their positions in the company. TD Asset Management Inc. purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $191,000. Victory Capital Management Inc. purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $641,000. JPMorgan Chase & Co. purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $2,325,000. Jennison Associates LLC purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $5,318,000. Finally, Versant Venture Management LLC purchased a new position in shares of Audentes Therapeutics during the third quarter valued at about $32,180,000. Hedge funds and other institutional investors own 71.00% of the company’s stock.

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics, Inc. (NASDAQ:BOLD) traded up 0.90% during midday trading on Friday, reaching $17.87. The company’s stock had a trading volume of 18,514 shares. The firm has a 50 day moving average price of $17.41 and a 200 day moving average price of $16.37. The firm’s market capitalization is $388.23 million. Audentes Therapeutics, Inc. has a 1-year low of $13.06 and a 1-year high of $20.74.

COPYRIGHT VIOLATION NOTICE: “BlackRock Advisors LLC Invests $3,564,000 in Audentes Therapeutics, Inc. (BOLD)” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this story can be accessed at http://www.dailypolitical.com/2017/01/13/blackrock-advisors-llc-invests-3564000-in-audentes-therapeutics-inc-bold.html.

BOLD has been the topic of several research analyst reports. Piper Jaffray Companies set a $24.00 price objective on Audentes Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 10th. Zacks Investment Research upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, December 5th.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

5 Day Chart for NASDAQ:BOLD

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics, Inc. (NASDAQ:BOLD).

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.